[Reactivation of hepatitis B virus in patients with hematological neoplasms].
Takkenberg
R B
RB
Academisch Medisch Centrum/Universiteit van Amsterdam. r.b.takkenberg@amc.uva.nl
Zaaijer
Hans L
HL
ten Cate
David F
DF
Biemond
Bart J
BJ
Jansen
Peter L M
PL
Reesink
Henk W
HW
D000305:Adrenal Cortex Hormones / Q000009:adverse effects / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D005260:Female; D006086:Graft vs Host Disease; D019337:Hematologic Neoplasms / Q000276:immunology / Q000628:therapy*; D006509:Hepatitis B / Q000150:complications* / Q000453:epidemiology / Q000821:virology; D006515:Hepatitis B virus / Q000502:physiology*; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D019259:Lamivudine / Q000627:therapeutic use; D008297:Male; D012307:Risk Factors; D012737:Sex Factors; D019737:Transplants; D014775:Virus Activation
D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000998:Antiviral Agents; D019259:Lamivudine